PubMed:32150618 / 0-189 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":32,"end":42},"obj":"GO:0042995"},{"id":"T2","span":{"begin":73,"end":91},"obj":"CHEBI:5801"},{"id":"T3","span":{"begin":73,"end":91},"obj":"DG_20"},{"id":"T4","span":{"begin":73,"end":91},"obj":"CHEBI:5801"},{"id":"T5","span":{"begin":113,"end":160},"obj":"SP_7"},{"id":"T6","span":{"begin":162,"end":172},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-PAS-Enju","denotations":[{"id":"EnjuParser_T0","span":{"begin":0,"end":2},"obj":"IN"},{"id":"EnjuParser_T1","span":{"begin":3,"end":8},"obj":"NNP"},{"id":"EnjuParser_T2","span":{"begin":9,"end":18},"obj":"JJ"},{"id":"EnjuParser_T3","span":{"begin":19,"end":27},"obj":"NN"},{"id":"EnjuParser_T4","span":{"begin":28,"end":31},"obj":"CC"},{"id":"EnjuParser_T5","span":{"begin":32,"end":42},"obj":"NN"},{"id":"EnjuParser_T6","span":{"begin":43,"end":45},"obj":"IN"},{"id":"EnjuParser_T7","span":{"begin":46,"end":55},"obj":"NNP"},{"id":"EnjuParser_T8","span":{"begin":56,"end":62},"obj":"NNP"},{"id":"EnjuParser_T9","span":{"begin":63,"end":69},"obj":"NNP"},{"id":"EnjuParser_T10","span":{"begin":70,"end":72},"obj":"IN"},{"id":"EnjuParser_T11","span":{"begin":73,"end":91},"obj":"NN"},{"id":"EnjuParser_T12","span":{"begin":92,"end":95},"obj":"IN"},{"id":"EnjuParser_T13","span":{"begin":96,"end":99},"obj":"DT"},{"id":"EnjuParser_T14","span":{"begin":100,"end":109},"obj":"NN"},{"id":"EnjuParser_T15","span":{"begin":110,"end":112},"obj":"IN"},{"id":"EnjuParser_T16","span":{"begin":113,"end":119},"obj":"NNP"},{"id":"EnjuParser_T17","span":{"begin":120,"end":125},"obj":"NNP"},{"id":"EnjuParser_T18","span":{"begin":126,"end":137},"obj":"NNP"},{"id":"EnjuParser_T19","span":{"begin":138,"end":146},"obj":"NNP"},{"id":"EnjuParser_T20","span":{"begin":147,"end":158},"obj":"NN"},{"id":"EnjuParser_T21","span":{"begin":159,"end":160},"obj":"CD"},{"id":"EnjuParser_T22","span":{"begin":161,"end":162},"obj":"-LRB-"},{"id":"EnjuParser_T23","span":{"begin":162,"end":172},"obj":"NN"},{"id":"EnjuParser_T24","span":{"begin":172,"end":173},"obj":"-RRB-"},{"id":"EnjuParser_T25","span":{"begin":175,"end":185},"obj":"NN"},{"id":"EnjuParser_T26","span":{"begin":185,"end":186},"obj":"-COLON-"}],"relations":[{"id":"EnjuParser_R0","pred":"arg2Of","subj":"EnjuParser_T4","obj":"EnjuParser_T0"},{"id":"EnjuParser_R1","pred":"arg1Of","subj":"EnjuParser_T3","obj":"EnjuParser_T1"},{"id":"EnjuParser_R2","pred":"arg1Of","subj":"EnjuParser_T3","obj":"EnjuParser_T2"},{"id":"EnjuParser_R3","pred":"arg1Of","subj":"EnjuParser_T3","obj":"EnjuParser_T4"},{"id":"EnjuParser_R4","pred":"arg2Of","subj":"EnjuParser_T5","obj":"EnjuParser_T4"},{"id":"EnjuParser_R5","pred":"arg1Of","subj":"EnjuParser_T5","obj":"EnjuParser_T6"},{"id":"EnjuParser_R6","pred":"arg2Of","subj":"EnjuParser_T9","obj":"EnjuParser_T6"},{"id":"EnjuParser_R7","pred":"arg1Of","subj":"EnjuParser_T9","obj":"EnjuParser_T7"},{"id":"EnjuParser_R8","pred":"arg1Of","subj":"EnjuParser_T9","obj":"EnjuParser_T8"},{"id":"EnjuParser_R9","pred":"arg1Of","subj":"EnjuParser_T9","obj":"EnjuParser_T10"},{"id":"EnjuParser_R10","pred":"arg2Of","subj":"EnjuParser_T11","obj":"EnjuParser_T10"},{"id":"EnjuParser_R11","pred":"arg1Of","subj":"EnjuParser_T5","obj":"EnjuParser_T12"},{"id":"EnjuParser_R12","pred":"arg2Of","subj":"EnjuParser_T14","obj":"EnjuParser_T12"},{"id":"EnjuParser_R13","pred":"arg1Of","subj":"EnjuParser_T14","obj":"EnjuParser_T13"},{"id":"EnjuParser_R14","pred":"arg1Of","subj":"EnjuParser_T14","obj":"EnjuParser_T15"},{"id":"EnjuParser_R15","pred":"arg2Of","subj":"EnjuParser_T20","obj":"EnjuParser_T15"},{"id":"EnjuParser_R16","pred":"arg1Of","subj":"EnjuParser_T19","obj":"EnjuParser_T16"},{"id":"EnjuParser_R17","pred":"arg1Of","subj":"EnjuParser_T19","obj":"EnjuParser_T17"},{"id":"EnjuParser_R18","pred":"arg1Of","subj":"EnjuParser_T19","obj":"EnjuParser_T18"},{"id":"EnjuParser_R19","pred":"arg1Of","subj":"EnjuParser_T20","obj":"EnjuParser_T19"},{"id":"EnjuParser_R20","pred":"arg1Of","subj":"EnjuParser_T20","obj":"EnjuParser_T21"},{"id":"EnjuParser_R21","pred":"arg1Of","subj":"EnjuParser_T20","obj":"EnjuParser_T22"},{"id":"EnjuParser_R22","pred":"arg2Of","subj":"EnjuParser_T23","obj":"EnjuParser_T22"},{"id":"EnjuParser_R23","pred":"arg3Of","subj":"EnjuParser_T24","obj":"EnjuParser_T22"},{"id":"EnjuParser_R24","pred":"arg1Of","subj":"EnjuParser_T25","obj":"EnjuParser_T26"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-ArguminSci","denotations":[{"id":"T1","span":{"begin":0,"end":174},"obj":"DRI_Background"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-OGER","denotations":[{"id":"T1","span":{"begin":73,"end":91},"obj":"CHEBI:5801"},{"id":"T1","span":{"begin":162,"end":166},"obj":"PR:000014459"}],"namespaces":[{"prefix":"PR","uri":"http://purl.obolibrary.org/obo/PR_"},{"prefix":"UBERON","uri":"http://purl.obolibrary.org/obo/UBERON_"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-PubTatorCentral","denotations":[{"id":"T1","span":{"begin":113,"end":137},"obj":"Disease:MESH:D045169"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-sentences-v1","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":174},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":175,"end":186},"obj":"Sentence"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-TimeML","denotations":[{"id":"tok1","span":{"begin":0,"end":2},"obj":"IN"},{"id":"tok2","span":{"begin":3,"end":8},"obj":"NNP"},{"id":"tok3","span":{"begin":9,"end":18},"obj":"NNP"},{"id":"tok4","span":{"begin":19,"end":27},"obj":"NN"},{"id":"tok5","span":{"begin":28,"end":31},"obj":"CC"},{"id":"tok6","span":{"begin":32,"end":42},"obj":"NNP"},{"id":"tok7","span":{"begin":43,"end":45},"obj":"IN"},{"id":"tok8","span":{"begin":46,"end":55},"obj":"NNP"},{"id":"tok9","span":{"begin":56,"end":62},"obj":"NNP"},{"id":"tok10","span":{"begin":63,"end":69},"obj":"NNP"},{"id":"tok11","span":{"begin":70,"end":72},"obj":"IN"},{"id":"tok12","span":{"begin":73,"end":91},"obj":"NNP"},{"id":"tok13","span":{"begin":92,"end":95},"obj":"IN"},{"id":"tok14","span":{"begin":96,"end":99},"obj":"DT"},{"id":"tok15","span":{"begin":100,"end":109},"obj":"NNP"},{"id":"tok16","span":{"begin":110,"end":112},"obj":"IN"},{"id":"tok17","span":{"begin":113,"end":119},"obj":"NNP"},{"id":"tok18","span":{"begin":120,"end":125},"obj":"NNP"},{"id":"tok19","span":{"begin":126,"end":137},"obj":"JJ"},{"id":"tok20","span":{"begin":138,"end":146},"obj":"NNP"},{"id":"tok21","span":{"begin":147,"end":158},"obj":"NNP"},{"id":"tok22","span":{"begin":159,"end":160},"obj":"CD"},{"id":"tok23","span":{"begin":161,"end":162},"obj":"("},{"id":"tok24","span":{"begin":162,"end":171},"obj":"NNP"},{"id":"tok25","span":{"begin":171,"end":172},"obj":"LS"},{"id":"tok26","span":{"begin":172,"end":173},"obj":")"},{"id":"tok27","span":{"begin":173,"end":174},"obj":"."},{"id":"tok28","span":{"begin":175,"end":185},"obj":"NNP"},{"id":"tok29","span":{"begin":185,"end":186},"obj":":"},{"id":"lookup1","span":{"begin":3,"end":8},"obj":"organization"},{"id":"lookup2","span":{"begin":63,"end":69},"obj":"org_key"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-PD-MONDO-v1","denotations":[{"id":"T1","span":{"begin":113,"end":160},"obj":"Disease"},{"id":"T2","span":{"begin":162,"end":170},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":113,"end":160},"obj":"Disease"},{"id":"T2","span":{"begin":162,"end":170},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":19,"end":27},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":174},"obj":"Sentence"},{"id":"T2","span":{"begin":175,"end":186},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}

{"project":"LitCovid-PubTator","denotations":[{"id":"3","span":{"begin":73,"end":91},"obj":"Chemical"},{"id":"4","span":{"begin":113,"end":160},"obj":"Species"},{"id":"5","span":{"begin":162,"end":172},"obj":"Species"}],"attributes":[{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:D006886"},{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"Tax:2697049"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\nBACKGROUND: Th"}